Completed

NCT Number: NCT04322019

Prescription Strategies of Amikacin in Intensive Care Patients on Renal Replacement Therapy: an Observational Prospective Multicenter Study

Amikacin is the aminoglycoside of choice for treatment of severe infections in intensive care. An achievement of its objectives in pharmacokinetics and pharmacodynamics is difficult in intensive care patients because of modification of their volume of distribution and renal clearance. Acute renal failure requiring renal replacement therapy is frequent in intensive care. Extrarenal purification modalities (continuous versus intermittent, type of dialysis membrane), which can influence amikacin clearance, are multiple and teams dependent. Guidelines of good practice for Amikacin in intensive care patients do not exist.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Amikacin Treatment

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Damien JOLLY

Reims, France

About this study

The aim of this study is to describe strategies of prescription and monitoring of Amikacin in intensive care patients on renal replacement therapy.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

patients in intensive care
patients on extrarenal replacement
patients with Amikacin treatment
patients accepting to participate in the study

Exclusion criteria

patients less than 18 years old
pregnant women
patients with Amikacin treatment in the previous 7 days

Treatment and study plan

data record

Other

Data record

Primary outcomes

Measurement of maximum concentration observed

Time frame: Day 0

Monitoring of Amikacin treatment using measurement of maximum concentration observed performed or not

Sponsors and collaborators

Lead sponsor

CHU de Reims